¼¼°èÀÇ ½Å¼Ó ÀÇ·á Áø´Ü ŰƮ ½ÃÀå
Rapid Medical Diagnostic Kits
»óǰÄÚµå : 1760897
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 07¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 166 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,150,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,452,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

½Å¼Ó ÀÇ·á Áø´Ü ŰƮ ¼¼°è ½ÃÀåÀº 2030³â±îÁö 189¾ï ´Þ·¯¿¡ À̸¦ Àü¸Á

2024³â¿¡ 153¾ï ´Þ·¯·Î ÃßÁ¤µÇ´Â ½Å¼Ó ÀÇ·á Áø´Ü ŰƮ ¼¼°è ½ÃÀåÀº ºÐ¼® ±â°£ÀÎ 2024-2030³â CAGR 3.6%·Î ¼ºÀåÇÏ¿© 2030³â¿¡´Â 189¾ï ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. º» º¸°í¼­¿¡¼­ ºÐ¼®ÇÑ ºÎ¹® Áß ÇϳªÀÎ OTC(Over the Counter) ŰƮ´Â CAGR 4.0%¸¦ ³ªÅ¸³»°í, ºÐ¼® ±â°£ Á¾·á±îÁö 107¾ï ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. »ó¾÷¿ë ŰƮ ºÐ¾ßÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£Áß CAGR 3.2%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 41¾ï ´Þ·¯·Î ÃßÁ¤, Áß±¹Àº CAGR6.0%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ ½Å¼Ó ÀÇ·á Áø´Ü ŰƮ ½ÃÀåÀº 2024³â¿¡ 41¾ï ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ °æÁ¦´ë±¹ÀÎ Áß±¹Àº 2030³â±îÁö 39¾ï ´Þ·¯ ±Ô¸ð¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, ºÐ¼® ±â°£ÀÎ 2024-2030³â CAGRÀº 6.0%·Î ¿¹»óµË´Ï´Ù. ±âŸ ÁÖ¸ñÇØ¾ß ÇÒ Áö¿ªº° ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖÀ¸¸ç, ºÐ¼® ±â°£Áß CAGRÀº °¢°¢ 2.4%¿Í 2.9%¸¦ º¸ÀÏ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR 2.5%¸¦ º¸ÀÏ Àü¸ÁÀÔ´Ï´Ù.

¼¼°è ½Å¼Ó ÀÇ·á Áø´Ü ŰƮ ½ÃÀå - ÁÖ¿ä µ¿Çâ ¹× ÃËÁø¿äÀÎ Á¤¸®

½Å¼Ó ÀÇ·á Áø´Ü ŰƮ´Â ¹«¾ùÀ̸ç, ¾î¶»°Ô ÇコÄɾ Çõ¸íÀ» ÀÏÀ¸Å°°í Àִ°¡?

½Å¼Ó ÀÇ·á Áø´Ü ŰƮ´Â Áúº´, °¨¿° ¹× °Ç°­ »óŸ¦ ½Å¼ÓÇϰí Á¤È®ÇÏ°Ô °¨ÁöÇÏ¿© ÀÇ·áÁøÀÌ Àû½Ã¿¡ Á¤º¸¿¡ ÀÔ°¢ÇÑ ÀÇ»ç °áÁ¤À» ³»¸± ¼ö ÀÖµµ·Ï ¼³°èµÈ Àü¿ë µµ±¸ÀÔ´Ï´Ù. ÀÌ·¯ÇÑ Å°Æ®¿¡´Â ÀϹÝÀûÀ¸·Î Ç÷¾×, Ÿ¾×, ¼Òº¯°ú °°Àº ü¾×¿¡ Æ÷ÇÔµÈ Æ¯Á¤ ¹ÙÀÌ¿À¸¶Ä¿¿Í ¹ÝÀÀÇÏ´Â ½Ã¾à, Å×½ºÆ® ½ºÆ®¸³ ¹× ±âŸ ÀÏȸ¿ë ±¸¼ºÇ°ÀÌ Æ÷ÇԵǾî ÀÖ¾î ¸î ºÐ ¾È¿¡ °á°ú¸¦ ¾òÀ» ¼ö ÀÖ½À´Ï´Ù. °á°ú°¡ ³ª¿À±â±îÁö ¸î ½Ã°£¿¡¼­ ¸çÄ¥ÀÌ °É¸®´Â ±âÁ¸ ½ÇÇè½Ç °Ë»ç¿Í ´Þ¸®, ½Å¼Ó ÀÇ·á Áø´Ü ŰƮ´Â ÈÞ´ë°¡ °¡´ÉÇÏ°í »ç¿ëÀÌ °£ÆíÇϸç ÃÖ¼ÒÇÑÀÇ ÀÎÇÁ¶ó°¡ ÇÊ¿äÇϱ⠶§¹®¿¡ ÇöÀå °Ë»ç¿¡ ¸Å¿ì ÀûÇÕÇÕ´Ï´Ù. ÀÌ ¶§¹®¿¡ ÀÓ»ó ÇöÀå»Ó¸¸ ¾Æ´Ï¶ó ÀÇ·á Á¢±Ù¼ºÀÌ Á¦ÇÑÀûÀÎ ¿ÀÁö³ª ÀÚ¿øÀÌ ºÎÁ·ÇÑ Áö¿ª¿¡¼­µµ ±ÍÁßÇÑ ÀÚ»êÀÌ µÇ°í ÀÖ½À´Ï´Ù. ½Å¼Ó ÀÇ·á Áø´Ü ŰƮ´Â Äڷγª19, ¸»¶ó¸®¾Æ, HIV¿Í °°Àº °¨¿°¼º ÁúȯºÎÅÍ ´ç´¢º´, ½ÉÇ÷°ü Áúȯ°ú °°Àº ¸¸¼ºÁúȯ±îÁö ´Ù¾çÇÑ ÁúȯÀÇ °ËÃâ¿¡ ³Î¸® »ç¿ëµÇ°í ÀÖ½À´Ï´Ù. Áï°¢ÀûÀÎ °á°ú¸¦ ¾òÀ» ¼ö Àֱ⠶§¹®¿¡ ÀÇ·á ¼­ºñ½º Á¦°ø¾÷ü°¡ Áúº´À» ¼±º°, Áø´Ü ¹× °ü¸®ÇÏ´Â ¹æ½ÄÀÌ ¿ÏÀüÈ÷ ´Þ¶óÁ³½À´Ï´Ù.

ÀÌ·¯ÇÑ Å°Æ®ÀÇ ±Þ¼ÓÇÑ º¸±ÞÀº ºÐ»êÇü ÇコÄÉ¾î ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡¿Í ¿¹¹æ ÀÇ·á¿¡ ´ëÇÑ °ü½É Áõ°¡·Î ÀÎÇØ °¡¼ÓÈ­µÇ°í ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, Äڷγª19 ÆÒµ¥¹Í ±â°£ µ¿¾È ½Å¼Ó ÀÇ·á Áø´Ü ŰƮ´Â ±¤¹üÀ§ÇÑ °Ë»ç ¹× °ËÁø ³ë·Â¿¡¼­ ¸Å¿ì Áß¿äÇÑ ¿ªÇÒÀ» ¼öÇàÇÏ¿© Áý´Ü °Ë»ç¿Í °¨¿°ÀÚÀÇ Àû½Ã °Ý¸®¸¦ °¡´ÉÇÏ°Ô Çß½À´Ï´Ù. ÀÌ·¯ÇÑ Å°Æ®ÀÇ ¹ü¿ë¼º°ú »ç¿ë ÆíÀǼºÀº ºñÀü¹®°¡¿Í Áö¿ª ÀÇ·áÁøÀ» Æ÷ÇÔÇÑ ´Ù¾çÇÑ ÀÇ·áÁøÀÌ Áø´Ü °Ë»ç¸¦ ½Ç½ÃÇÒ ¼ö ÀÖµµ·Ï ÇÏ¿© Áø´Ü ¼­ºñ½º¿¡ ´ëÇÑ Á¢±Ù¼ºÀ» ¹ÎÁÖÈ­Çß½À´Ï´Ù. ¶ÇÇÑ, Ãø¸é È帧 ºÐ¼®, ¸é¿ª ºÐ¼®, ºÐÀÚÁø´ÜÇÐ µî ÷´Ü ±â¼ú °³¹ßÀÌ ÁøÇàµÇ¸é¼­ À̵é ŰƮÀÇ ¹Î°¨µµ, ƯÀ̵µ, Á¾ÇÕÀûÀÎ ½Å·Ú¼ºÀÌ Çâ»óµÇ°í ÀÖ½À´Ï´Ù. Àü ¼¼°è ÀÇ·á ½Ã½ºÅÛÀÌ Á¶±â Áø´Ü°ú ½Å¼ÓÇÑ ´ëÀÀÀ» ¿ì¼±½ÃÇÏ´Â °¡¿îµ¥, ½Å¼Ó ÀÇ·á Áø´Ü ŰƮÀÇ ¿ªÇÒÀÌ È®´ëµÇ¾î Áø´ÜÀÇ Àü¸ÁÀ» À籸¼ºÇÏ°í º¸´Ù Àû±ØÀûÀÌ°í °³ÀÎÈ­µÈ ÀÇ·á ¼­ºñ½º¸¦ Á¦°øÇÒ ¼ö ÀÖ´Â ±æÀ» ¿­¾îÁÙ °ÍÀ¸·Î ±â´ëµË´Ï´Ù.

±â¼ú Çõ½ÅÀº ½Å¼Ó ÀÇ·á Áø´Ü ŰƮÀÇ ¹Ì·¡¸¦ ¾î¶»°Ô Çü¼ºÇϰí Àִ°¡?

±â¼ú ¹ßÀüÀº ½Å¼Ó ÀÇ·á Áø´Ü ŰƮÀÇ ÁøÈ­ÇÏ´Â ´É·Â°ú È¿´ÉÀÇ ÇÙ½ÉÀÔ´Ï´Ù. ÀÌ ºÐ¾ß¿¡¼­ °¡Àå Áß¿äÇÑ ±â¼ú Çõ½Å Áß Çϳª´Â ÁßÇÕÈ¿¼Ò¿¬¼â¹ÝÀÀ(PCR) ¹× ·çÇÁ ¸Å°³ µî¿ÂÁõÆø¹ý(LAMP)°ú °°Àº ºÐÀÚÁø´Ü ±â¼úÀÇ °³¹ßÀÔ´Ï´Ù. ÀÌ·¯ÇÑ ±â¼úÀº º´¿øÃ¼¿¡¼­ ƯÁ¤ À¯Àü¹°ÁúÀ» °ËÃâÇÒ ¼ö ÀÖ°Ô ÇÏ¿© °¨¿° ¿äÀÎÀ» ½Å¼ÓÇÏ°í ¹Î°¨ÇÏ°Ô ½Äº°ÇÒ ¼ö ÀÖ°Ô ÇØÁÝ´Ï´Ù. º¹ÀâÇÑ ½ÇÇè½Ç ¼³Á¤°ú ¼÷·ÃµÈ ÀηÂÀÌ ÇÊ¿äÇÑ ±âÁ¸ ¹æ¹ý°ú ´Þ¸®, ºÐÀÚÁø´ÜÇÐÀº ÇöÀç ¼ÒÇüÀÇ ÈÞ´ë¿ë ÀåÄ¡¸¦ »ç¿ëÇÏ¿© ¸î ºÐ ¾È¿¡ °á°ú¸¦ ¾òÀ» ¼ö ÀÖ´Â ¼ÒÇü ±â±â¸¦ »ç¿ëÇÏ¿© ¼öÇà ÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ´Â È¿°úÀûÀÎ Ä¡·á¿Í ºÀ¼â¸¦ À§ÇØ Àû½Ã¿¡ Áø´ÜÇÏ´Â °ÍÀÌ ¸Å¿ì Áß¿äÇÑ Äڷγª19³ª µ¶°¨°ú °°Àº ¹ÙÀÌ·¯½º °¨¿°À» °¨ÁöÇÏ´Â µ¥ ƯÈ÷ À¯¿ëÇÏ´Ù´Â °ÍÀÌ ÀÔÁõµÇ¾ú½À´Ï´Ù. ¶ÇÇÑ, ¹ÙÀÌ¿À¼¾¼­ ±â¼úÀÇ ¹ßÀüÀ¸·Î ¸ð¹ÙÀÏ ±â±â¿Í ÅëÇյǴ µðÁöÅÐ Áø´Ü ŰƮÀÇ °³¹ßÀÌ °¡´ÉÇØÁ® ½Ç½Ã°£ µ¥ÀÌÅÍ ºÐ¼® ¹× ¿ø°Ý ¸ð´ÏÅ͸µ ±â´ÉÀ» Á¦°øÇÒ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù. ÀÌ·¯ÇÑ ¿¬°á¼ºÀ» ÅëÇØ ÀÇ·á ¼­ºñ½º Á¦°ø¾÷ü´Â ȯÀÚÀÇ °Ç°­ »óŸ¦ º¸´Ù Á¾ÇÕÀûÀ¸·Î ÃßÀûÇÏ°í µ¥ÀÌÅÍ ±â¹Ý ÀÇ»ç°áÁ¤À» ³»¸± ¼ö ÀÖ°Ô µÇ¾î °³ÀÎ ¸ÂÃãÇü ÀÇ·á¿¡¼­ ½Å¼ÓÇÑ Áø´ÜÀÇ ¿ªÇÒÀ» ´õ¿í °­È­ÇÒ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù.

¶Ç ´Ù¸¥ Çõ½ÅÀº Áø´Ü ŰƮ ¼³°è¿¡ ³ª³ë ±â¼úÀ» Àû¿ëÇÑ °ÍÀÔ´Ï´Ù. ±Ý ³ª³ëÀÔÀÚ³ª ¾çÀÚÁ¡°ú °°Àº ³ª³ë ½ºÄÉÀÏ ¹°ÁúÀº ¹Î°¨µµ¿Í ƯÀ̼ºÀ» Çâ»ó½Ã۱â À§ÇØ Áø´Ü ºÐ¼®¿¡ ÅëÇյǰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¹°ÁúÀº ½ÅÈ£¸¦ ÁõÆøÇÏ°í ¹Ì·®ÀÇ Áúº´ ¸¶Ä¿¸¦ °ËÃâÇÒ ¼ö ÀÖ¾î ÀÌÀüº¸´Ù ´õ À̸¥ ½Ã±â¿¡ Áúº´À» ½Äº°ÇÒ ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ, Ãø¸é È帧 ºÐ¼® ±â¼úÀÇ Ã¤ÅÃÀº Àú·ÅÇÏ°í »ç¿ëÇϱ⠽¬¿î ŰƮÀÇ Á¦Á¶¿¡ Çõ¸íÀ» °¡Á®¿ÔÀ¸¸ç, °¡Á¤ ³» °Ë»çÀÇ Ç¥ÁØÀ¸·Î ÀÚ¸® Àâ¾Ò½À´Ï´Ù. ÃÖ±ÙÀÇ ¹ßÀüÀº ÇϳªÀÇ Å°Æ®·Î ¿©·¯ ÁúȯÀ» µ¿½Ã¿¡ °Ë»çÇÒ ¼ö ÀÖ´Â ¸ÖƼÇ÷º½º °Ë»ç ±â´É¿¡µµ ÃÊÁ¡À» ¸ÂÃß°í ÀÖ¾î Á¾ÇÕÀûÀÎ °Ç°­ °ËÁø¿¡ ÀÌ»óÀûÀÔ´Ï´Ù. ÀÌ ºÐ¾ßÀÇ ¿¬±¸ °³¹ßÀÌ ÁøÇàµÊ¿¡ µû¶ó ÀΰøÁö´É(AI)°ú ¸Ó½Å·¯´×ÀÌ Áø´Ü Ç÷§Æû¿¡ ÅëÇÕµÇ¾î °á°úÀÇ ÀÚµ¿ ÇØ¼®°ú ¿¹Ãø ºÐ¼®¿¡ »õ·Î¿î °¡´É¼ºÀ» ¿­¾îÁÙ °ÍÀ¸·Î ±â´ëµË´Ï´Ù. ÀÌ·¯ÇÑ ±â¼ú Çõ½ÅÀº ½Å¼Ó ÀÇ·á Áø´Ü ŰƮ¸¦ ´õ¿í Æí¸®Çϰí, È¿À²ÀûÀ̸ç, Á¤È®ÇÏ°Ô ¸¸µé°í, ÇコÄɾî Áø´ÜÀÇ ¹Ì·¡ Ãʼ®À¸·Î¼­ÀÇ ¿ªÇÒÀ» È®°íÈ÷ ÇÒ ¼ö ÀÖÀ» °ÍÀÔ´Ï´Ù.

´Ù¾çÇÑ ÇコÄɾî ÇöÀå¿¡¼­ ½Å¼Ó ÀÇ·á Áø´Ü ŰƮ µµÀÔÀ» ÃËÁøÇÏ´Â ¿äÀÎÀº ¹«¾ùÀΰ¡?

½Å¼Ó ÀÇ·á Áø´Ü ŰƮÀÇ º¸±ÞÀº Àü¿°º´ÀÇ À¯Çà, ¿¹¹æ ÀÇ·á¿¡ ´ëÇÑ °ü½É Áõ°¡, ºÐ»êÇü °Ë»ç ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡ µî ´Ù¾çÇÑ ¿äÀÎÀÌ º¹ÇÕÀûÀ¸·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù. »çÇ϶ó »ç¸· À̳² ¾ÆÇÁ¸®Ä«³ª µ¿³²¾Æ½Ã¾Æ ÀϺΠÁö¿ª°ú °°ÀÌ Áúº´ ºÎ´ãÀÌ Å« Áö¿ª¿¡¼­´Â ¸»¶ó¸®¾Æ, °áÇÙ, HIV¿Í °°Àº dzÅ亴°ú ½Î¿ì´Â µ¥ ÀÖ¾î ½Å¼Ó ÀÇ·á Áø´Ü ŰƮ°¡ ÇʼöÀûÀÎ µµ±¸°¡ µÇ°í ÀÖ½À´Ï´Ù. ÀÌ Å°Æ®¸¦ »ç¿ëÇϸé ÀÇ·áÁøÀÌ È¯ÀÚ¸¦ ½Å¼ÓÇÏ°Ô Áø´ÜÇϰí Ä¡·áÇÒ ¼ö ÀÖ¾î Ä¡·á °á°ú¸¦ °³¼±ÇÏ°í °¨¿° È®»êÀ» ¹æÁöÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ¸¶Âù°¡Áö·Î °í¼Òµæ ±¹°¡¿¡¼­´Â Áúº´ÀÇ Á¶±â ¹ß°ß°ú °³ÀÎ ¸ÂÃãÇü ÀÇ·á¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁü¿¡ µû¶ó ½Å¼Ó Áø´Ü¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. °í·ÉÈ­¿Í ´ç´¢º´, ½ÉÇ÷°ü Áúȯ°ú °°Àº ¸¸¼ºÁúȯÀÇ À¯º´·üÀÌ Áõ°¡ÇÔ¿¡ µû¶ó, °¡Á¤À̳ª Áö¿ª Áø·á¼Ò µî ±âÁ¸ ÀÇ·á ȯ°æ ¹Û¿¡¼­ »ç¿ëÇÒ ¼ö ÀÖ´Â Áø´Ü µµ±¸¿¡ ´ëÇÑ ¿ä±¸°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Ãß¼¼´Â Àüü ºñ¿ëÀ» ÁÙÀ̸鼭 ȯÀÚ °á°ú¸¦ °³¼±ÇÏ´Â µ¥ ÁßÁ¡À» µÎ´Â °¡Ä¡ ±â¹Ý ÀÇ·á·ÎÀÇ Àüȯ¿¡ ÀÇÇØ ´õ¿í °­È­µÇ°í ÀÖ½À´Ï´Ù.

½Å¼Ó ÀÇ·á Áø´Ü ŰƮÀÇ Ã¤Åÿ¡ ±â¿©ÇÏ´Â ¶Ç ´Ù¸¥ Áß¿äÇÑ ¿ä¼Ò´Â ÀÀ±Þ ¹× ±Þ¼º±â ÀÇ·á ÇöÀå¿¡¼­ÀÇ ½Å¼ÓÇÑ ÀÇ»ç°áÁ¤ÀÇ Çʿ伺ÀÔ´Ï´Ù. ÀÌ·¯ÇÑ È¯°æ¿¡¼­´Â ½Ã°£ÀÌ Áß¿äÇÑ ¿ä¼Ò·Î ÀÛ¿ëÇÏ´Â °æ¿ì°¡ ¸¹Àºµ¥, ½Å¼ÓÇÑ Áø´ÜÀ» ÅëÇØ ÀÇ·á Àü¹®°¡°¡ Ä¡·á °áÁ¤À» ³»¸®´Â µ¥ ÇÊ¿äÇÑ Á¤º¸¸¦ Áï½Ã ¾òÀ» ¼ö ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, ½ÉÀå ¸¶Ä¿ÀÇ ½Å¼ÓÇÑ °Ë»ç´Â ÀÀ±Þ½Ç¿¡¼­ ÈäÅëÀ¸·Î ³»¿øÇÑ È¯ÀÚÀÇ ½ÉÀ帶ºñ À§ÇèÀ» ½Å¼ÓÇÏ°Ô Æò°¡Çϰí Àû½Ã¿¡ °³ÀÔÇÒ ¼ö ÀÖµµ·Ï ÀÀ±Þ½Ç¿¡¼­ »ç¿ëµÇ°í ÀÖ½À´Ï´Ù. ¸¶Âù°¡Áö·Î, °¨¿°ÀÌ ¹ß»ýÇÏ¸é ½Å¼Ó ÀÇ·á Áø´Ü ŰƮ´Â °¨¿° »ç·Ê¸¦ ½Å¼ÓÇÏ°Ô ½Äº°ÇÏ°í °Ý¸®ÇÏ´Â µ¥ ÇʼöÀûÀÌ¸ç ±¤¹üÀ§ÇÑ °¨¿°À» ¿¹¹æÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ¼ÒºñÀÚµéÀÌ °Ç°­ °ü¸®¿¡ Àû±ØÀûÀÌ µÊ¿¡ µû¶ó °¡Á¤¿ë Å×½ºÆ® ŰƮÀÇ ¼ö¿ë°ú ¼ö¿ä°¡ Áõ°¡ÇÏ´Â °Íµµ ½ÃÀå ¼ºÀåÀÇ ÇÑ ¿äÀÎÀÔ´Ï´Ù. ÀÓ½Å, Ç÷´ç, ¼ºº´ µîÀÇ ÀÚ°¡ Áø´Ü ŰƮ´Â ÇÁ¶óÀ̹ö½Ã, ÆíÀǼº, ºü¸¥ °á°ú¿¡ ´ëÇÑ ¼±È£µµ°¡ ³ô¾ÆÁö¸é¼­ º¸ÆíÈ­µÇ°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¿äÀεéÀÌ ÀÇ·á ¼­ºñ½º Á¦°ø¿¡ Áö¼ÓÀûÀ¸·Î ¿µÇâÀ» ¹ÌÄ¡¸é¼­ ´Ù¾çÇÑ ÀÇ·á ȯ°æ¿¡¼­ ½Å¼Ó ÀÇ·á Áø´Ü ŰƮÀÇ Ã¤ÅÃÀÌ Áõ°¡ÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

½Å¼Ó ÀÇ·á Áø´Ü ŰƮ ¼¼°è ½ÃÀå ±Þ¼ºÀå ¿øµ¿·ÂÀº?

¼¼°è ½Å¼Ó ÀÇ·á Áø´Ü ŰƮ ½ÃÀåÀÇ ¼ºÀåÀº ±â¼ú ¹ßÀü, Àü¿°º´ ¹× ¸¸¼º ÁúȯÀÇ À¯Çà, ÇöÀå Áø´Ü¿¡ ´ëÇÑ Á߿伺 Áõ°¡ µî ¸î °¡Áö Áß¿äÇÑ ¿äÀο¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù. ÁÖ¿ä ¼ºÀå ¿äÀÎ Áß Çϳª´Â º¸´Ù Áøº¸µÇ°í ´ÙÀç´Ù´ÉÇÑ Áø´Ü ±â¼úÀÇ °³¹ßÀÌ ÁøÇàµÇ°í ÀÖ´Ù´Â Á¡ÀÔ´Ï´Ù. ·¦¿ÂĨ Ç÷§Æû, ¸¶ÀÌÅ©·ÎÇ÷çÀ̵ñ½º ÀåÄ¡, CRISPR ±â¹Ý Áø´Ü¹ý µîÀÇ ±â¼ú Çõ½ÅÀ¸·Î ÀÎÇØ ÃÖ¼ÒÇÑÀÇ »ùÇ÷Π´Ù¾çÇÑ Áúº´À» °¨ÁöÇÒ ¼ö ÀÖ´Â °í°¨µµ, °íÁ¤¹Ð ŰƮ°¡ °³¹ßµÇ°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¹ßÀüÀº ±âÁ¸ÀÇ ½ÇÇè½Ç ȯ°æ ¹Û¿¡¼­µµ º¹ÀâÇÑ Áø´Ü °Ë»ç¸¦ ¼öÇàÇÒ ¼ö ÀÖ°Ô ÇÔÀ¸·Î½á ºÐ»êÇü °Ë»ç ¹× °³ÀÎ ¸ÂÃãÇü ÀÇ·á·ÎÀÇ ÀüȯÀ» °¡¼ÓÈ­Çϰí ÀÖ½À´Ï´Ù. ¶Ç ´Ù¸¥ Áß¿äÇÑ ¿øµ¿·ÂÀº °¨¿°º´ ¹ß»ý·ü Áõ°¡¿Í À̸¦ °ü¸®Çϰí ÅëÁ¦Çϱâ À§ÇÑ ½Å¼ÓÇÑ Áø´Ü ¼Ö·ç¼ÇÀÇ Çʿ伺ÀÔ´Ï´Ù. ¿¹¸¦ µé¾î, Äڷγª19 ÆÒµ¥¹ÍÀº °øÁߺ¸°Ç ´ëÀÀ¿¡ ÀÖ¾î ½Å¼Ó ÀÇ·á Áø´Ü ŰƮÀÇ Áß¿äÇÑ ¿ªÇÒÀ» ºÎ°¢½ÃÄ×°í, Áø´Ü ±â¼ú°ú ÀÎÇÁ¶ó¿¡ ´ëÇÑ Àü·Ê ¾ø´Â ÅõÀÚ¸¦ Ã˹߽ÃÄ×½À´Ï´Ù.

¶ÇÇÑ, ¿¹¹æ ÀÇ·á ¹× Áúº´ Á¶±â ¹ß°ß¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁö¸é¼­ ½Å¼Ó ÀÇ·á Áø´Ü ŰƮ ½ÃÀå È®´ë¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. Àü ¼¼°è ÀÇ·á ½Ã½ºÅÛÀÌ º¸´Ù Àû±ØÀûÀÎ Á¢±Ù ¹æ½ÄÀ¸·Î ÀüȯÇÔ¿¡ µû¶ó °Ç°­ À§Çè°ú Áúº´À» Á¶±â¿¡ ¹ß°ßÇÒ ¼ö ÀÖ´Â µµ±¸¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ½Å¼Ó ÀÇ·á Áø´Ü ŰƮ´Â Áï°¢ÀûÀÎ °á°ú¸¦ Á¦°øÇϱ⠶§¹®¿¡ °Ç°­ °ËÁø ÇÁ·Î±×·¥À̳ª Á¤±â °ËÁø¿¡ ÀûÇÕÇϸç, Àû½Ã¿¡ °³ÀÔÇÏ°í °ü¸®ÇÒ ¼ö ÀÖµµ·Ï µ½½À´Ï´Ù. ¶ÇÇÑ, °Ç°­ °ü¸®¸¦ À§ÇØ Æí¸®ÇÏ°í °³ÀÎÈ­µÈ ¼Ö·ç¼ÇÀ» ã´Â ¼ÒºñÀÚ°¡ Áõ°¡ÇÔ¿¡ µû¶ó ÀçÅà Áø´ÜÀÇ Æ®·»µå°¡ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇϰí ÀÖÀ¸¸ç, ÀüÀÚ»ó°Å·¡ ¹× ¿ø°Ý ÀÇ·á Ç÷§ÆûÀÇ ºÎ»óÀ¸·Î ½Å¼Ó ÀÇ·á Áø´Ü ŰƮ¿¡ ´ëÇÑ Á¢±ÙÀÌ ´õ¿í ½¬¿öÁ® ¼ÒºñÀÚ°¡ ÀÌ·¯ÇÑ Á¦Ç°À» ½±°Ô ±¸¸ÅÇÏ°í »ç¿ëÇÒ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù. ½±°Ô ±¸¸ÅÇÒ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù. ÀÇ·á ½Ã½ºÅÛÀ» °­È­Çϰí Áúº´ °¨½Ã¸¦ °³¼±Çϱâ À§ÇÑ Á¤ºÎÀÇ ÀÌ´Ï¼ÅÆ¼ºêµµ ½ÃÀå ¼ºÀå¿¡ Áß¿äÇÑ ¿ªÇÒÀ» Çϰí ÀÖÀ¸¸ç, ¸¹Àº Á¤ºÎ°¡ ÀÓ»ó ¹× Áö¿ª»çȸ¿¡¼­ ½Å¼Ó Áø´Ü ±â¼úÀÇ µµÀÔÀ» Áö¿øÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¿äÀεéÀÌ º¹ÇÕÀûÀ¸·Î ÀÛ¿ëÇÏ¿© ¼¼°è ½Å¼Ó ÀÇ·á Áø´Ü ŰƮ ½ÃÀåÀº ±â¼ú Çõ½Å, Á¢±Ù¼º ³ôÀº ÇコÄɾ ´ëÇÑ ¼ö¿ä Áõ°¡, °øÁߺ¸°Ç ´ëºñ¿¡ ´ëÇÑ °ü½É Áõ°¡¿¡ ÈûÀÔ¾î °­·ÂÇÑ ¼ºÀå¼¼¸¦ º¸ÀÏ °ÍÀ¸·Î Àü¸ÁµË´Ï´Ù.

ºÎ¹®

Á¦Ç° À¯Çü(OTC ŰƮ, »ó¾÷¿ë ŰƮ);¿ëµµ(°¨¿°Áõ °Ë»ç, Ç÷´ç °Ë»ç, ÁöÁú °³¿ä °Ë»ç, ¸¶À½ ´ë»ç °Ë»ç, ºÒÀÓ ¹× ÀӽŠ°Ë»ç, µ¶¼º °Ë»ç, ±âŸ ¿ëµµ);ÃÖÁ¾ ¿ëµµ(º´¿ø ¹× Áø·á¼Ò, Áø´Ü ½ÇÇè½Ç, ȨÄɾî)

Á¶»ç ´ë»ó ±â¾÷ ¿¹(ÃÑ 27°³»ç)

AI ÅëÇÕ

Global Industry Analysts´Â À¯È¿ÇÑ Àü¹®°¡ ÄÁÅÙÃ÷¿Í AIÅø¿¡ ÀÇÇØ ½ÃÀå Á¤º¸¿Í °æÀï Á¤º¸¸¦ º¯ÇõÇϰí ÀÖ½À´Ï´Ù.

Global Industry Analysts´Â LLM³ª ¾÷°è °íÀ¯ SLM¸¦ Á¶È¸ÇÏ´Â ÀϹÝÀûÀÎ ±Ô¹ü¿¡ µû¸£´Â ´ë½Å¿¡, ºñµð¿À ±â·Ï, ºí·Î±×, °Ë»ö ¿£Áø Á¶»ç, ¹æ´ëÇÑ ¾çÀÇ ±â¾÷, Á¦Ç°/¼­ºñ½º, ½ÃÀå µ¥ÀÌÅÍ µî, Àü ¼¼°è Àü¹®°¡·ÎºÎÅÍ ¼öÁýÇÑ ÄÁÅÙÃ÷ ¸®Æ÷ÁöÅ丮¸¦ ±¸ÃàÇß½À´Ï´Ù.

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»»çÀÇ ±¹°¡, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±â¹ÝÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇß½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ¼öÀÍ¿ø°¡(COGS) Áõ°¡, ¼öÀͼº °¨¼Ò, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû ¹× °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

LSH
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Rapid Medical Diagnostic Kits Market to Reach US$18.9 Billion by 2030

The global market for Rapid Medical Diagnostic Kits estimated at US$15.3 Billion in the year 2024, is expected to reach US$18.9 Billion by 2030, growing at a CAGR of 3.6% over the analysis period 2024-2030. Over the Counter (OTC) Kits, one of the segments analyzed in the report, is expected to record a 4.0% CAGR and reach US$10.7 Billion by the end of the analysis period. Growth in the Professional Kits segment is estimated at 3.2% CAGR over the analysis period.

The U.S. Market is Estimated at US$4.1 Billion While China is Forecast to Grow at 6.0% CAGR

The Rapid Medical Diagnostic Kits market in the U.S. is estimated at US$4.1 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$3.9 Billion by the year 2030 trailing a CAGR of 6.0% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.4% and 2.9% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.5% CAGR.

Global Rapid Medical Diagnostic Kits Market - Key Trends & Drivers Summarized

What Are Rapid Medical Diagnostic Kits and How Are They Revolutionizing Healthcare?

Rapid Medical Diagnostic Kits are specialized tools designed to provide quick and accurate detection of diseases, infections, and health conditions, enabling healthcare providers to make timely and informed decisions. These kits typically include reagents, test strips, and other disposable components that react with specific biomarkers in bodily fluids such as blood, saliva, or urine to provide results within minutes. Unlike conventional laboratory testing, which can take hours or even days to yield results, rapid diagnostic kits are portable, easy to use, and require minimal infrastructure, making them highly suitable for point-of-care testing. This has made them a valuable asset not only in clinical settings but also in remote and resource-limited areas where access to healthcare is restricted. Rapid diagnostic kits are widely used to detect a range of conditions, from infectious diseases like COVID-19, malaria, and HIV to chronic conditions like diabetes and cardiovascular diseases. Their ability to deliver immediate results has transformed how healthcare providers approach disease screening, diagnosis, and management.

The rapid adoption of these kits has been accelerated by the growing need for decentralized healthcare solutions and the increasing focus on preventative care. During the COVID-19 pandemic, for example, rapid diagnostic kits played a pivotal role in widespread testing and screening efforts, allowing for mass testing and timely isolation of infected individuals. The versatility of these kits, combined with their ease of use, has enabled a broader range of healthcare professionals-including non-specialists and community health workers-to perform diagnostic tests, democratizing access to diagnostic services. In addition, the ongoing development of advanced technologies such as lateral flow assays, immunoassays, and molecular diagnostics has enhanced the sensitivity, specificity, and overall reliability of these kits. As healthcare systems around the world continue to prioritize early diagnosis and rapid response, the role of rapid medical diagnostic kits is expected to expand, reshaping the diagnostic landscape and paving the way for more proactive and personalized healthcare delivery.

How Are Technological Innovations Shaping The Future Of Rapid Medical Diagnostic Kits?

Technological advancements are at the heart of the evolving capabilities and effectiveness of rapid medical diagnostic kits. One of the most significant innovations in this field is the development of molecular diagnostic technologies such as polymerase chain reaction (PCR) and loop-mediated isothermal amplification (LAMP). These technologies allow for the detection of specific genetic material from pathogens, enabling rapid and highly sensitive identification of infectious agents. Unlike traditional methods that require complex laboratory setups and trained personnel, molecular diagnostics can now be performed using compact, portable devices that deliver results within a matter of minutes. This has proven particularly beneficial for the detection of viral infections such as COVID-19 and influenza, where timely diagnosis is crucial for effective treatment and containment. Additionally, advances in biosensor technology have enabled the development of digital diagnostic kits that integrate with mobile devices, providing real-time data analysis and remote monitoring capabilities. This connectivity allows healthcare providers to track patient health more comprehensively and make data-driven decisions, further enhancing the role of rapid diagnostics in personalized medicine.

Another transformative innovation is the application of nanotechnology in diagnostic kit design. Nanoscale materials such as gold nanoparticles and quantum dots are being incorporated into diagnostic assays to improve their sensitivity and specificity. These materials can amplify signals and detect even trace amounts of disease markers, making it possible to identify conditions at an earlier stage than ever before. Furthermore, the adoption of lateral flow assay technology has revolutionized the production of affordable and easy-to-use kits, which have become a staple in home-testing scenarios. Recent advancements have also focused on multiplex testing capabilities, where a single kit can simultaneously test for multiple conditions, making it ideal for comprehensive health screenings. As research and development in this field continue to progress, the integration of artificial intelligence (AI) and machine learning into diagnostic platforms is expected to open up new possibilities for automated result interpretation and predictive analytics. These innovations are poised to make rapid medical diagnostic kits more accessible, efficient, and accurate, cementing their role as a cornerstone in the future of healthcare diagnostics.

What Factors Are Driving The Adoption Of Rapid Medical Diagnostic Kits Across Different Healthcare Settings?

The widespread adoption of rapid medical diagnostic kits is being driven by a confluence of factors, including the rising prevalence of infectious diseases, increasing focus on preventive healthcare, and the growing need for decentralized testing solutions. In regions with high disease burden, such as sub-Saharan Africa and parts of Southeast Asia, rapid diagnostic kits have become essential tools in the fight against endemic diseases like malaria, tuberculosis, and HIV. These kits enable healthcare workers to diagnose and treat patients quickly, improving outcomes and preventing the spread of infections. Similarly, in high-income countries, the demand for rapid diagnostics is being fueled by the growing emphasis on early disease detection and personalized healthcare. With an aging population and the rising incidence of chronic conditions such as diabetes and cardiovascular diseases, there is an increasing need for diagnostic tools that can be used outside of traditional healthcare settings, such as at home or in community clinics. This trend is further reinforced by the shift towards value-based healthcare, where the focus is on improving patient outcomes while reducing overall costs.

Another significant factor contributing to the adoption of rapid medical diagnostic kits is the need for faster decision-making in emergency and acute care settings. In these environments, time is often a critical factor, and rapid diagnostics can provide healthcare professionals with immediate information to guide treatment decisions. For instance, rapid tests for cardiac markers are used in emergency rooms to quickly assess the risk of heart attack in patients presenting with chest pain, enabling timely intervention. Similarly, in the context of infectious disease outbreaks, rapid diagnostic kits are crucial for swift identification and isolation of cases, helping to prevent widespread transmission. The increasing acceptance and demand for home-testing kits is another driver of market growth, as consumers become more proactive in managing their health. Self-testing kits for conditions such as pregnancy, blood glucose levels, and sexually transmitted infections are becoming commonplace, driven by a growing preference for privacy, convenience, and faster results. As these factors continue to influence healthcare delivery, the adoption of rapid diagnostic kits is expected to increase across a diverse range of healthcare settings.

What Is Driving The Rapid Growth Of The Global Rapid Medical Diagnostic Kits Market?

The growth in the global Rapid Medical Diagnostic Kits market is driven by several key factors, including technological advancements, the increasing prevalence of infectious and chronic diseases, and the growing emphasis on point-of-care diagnostics. One of the primary growth drivers is the ongoing development of more sophisticated and versatile diagnostic technologies. Innovations such as lab-on-a-chip platforms, microfluidic devices, and CRISPR-based diagnostics are enabling the creation of highly sensitive and accurate kits that can detect a broad spectrum of conditions with minimal sample requirements. These advancements are making it possible to conduct complex diagnostic tests outside of traditional laboratory settings, accelerating the shift towards decentralized testing and personalized medicine. Another significant driver is the rising incidence of infectious diseases and the need for rapid diagnostic solutions to manage and contain outbreaks. The COVID-19 pandemic, for instance, highlighted the critical role of rapid diagnostic kits in public health responses, driving unprecedented investments in diagnostic technology and infrastructure.

Moreover, the growing focus on preventive healthcare and early disease detection is contributing to the expansion of the rapid diagnostic kits market. As healthcare systems around the world shift towards a more proactive approach, there is increasing demand for tools that enable early identification of health risks and conditions. Rapid diagnostic kits, with their ability to provide immediate results, are ideal for health screening programs and routine check-ups, allowing for timely intervention and management. Additionally, the trend towards home-based diagnostics is driving market growth, as more consumers seek convenient and private solutions for managing their health. The rise of e-commerce and telemedicine platforms has further facilitated access to rapid diagnostic kits, making it easier for consumers to purchase and use these products. Government initiatives to strengthen healthcare systems and improve disease surveillance are also playing a crucial role in market growth, with many governments supporting the deployment of rapid diagnostic technologies in both clinical and community settings. As these factors converge, the global rapid medical diagnostic kits market is poised for robust growth, driven by innovation, increasing demand for accessible healthcare, and a heightened focus on public health preparedness.

SCOPE OF STUDY:

The report analyzes the Rapid Medical Diagnostic Kits market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product Type (Over the Counter (OTC) Kits, Professional Kits); Application (Infectious Disease Testing, Blood Glucose Testing, Lipid Profile Testing, Cardiometabolic Testing, Fertility & Pregnancy Testing, Toxicology Testing, Other Applications); End-Use (Hospitals & Clinics, Diagnostic Laboratories, Home Care)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 27 Featured) -

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â